Laboratory for Advanced Medicine Provides Select Doctors with Revolutionary New IvyGene Technology for Early Cancer Diagnosis and Detection

IRVINE, Calif., March 26, 2018 /PRNewswire/ -- Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing cutting-edge technologies for the early diagnosis and intervention of cancer, today announced that the Company is providing its groundbreaking new IvyGene^® technology to select doctors in the U.S., with plans to commercialize IvyGene for the general public later this year. IvyGene is an accurate, non-invasive blood test that uses a multi-target approach derived from advanced DNA sequencing methods to detect the DNA methylation pattern of circulating tumor DNA (ctDNA) in blood samples to confirm the presence of malignant cancer and give measurable information about the disease at the time of testing.

"The statistics for developing cancer in today's society are staggering: 42 percent of men and 38 percent of women will be diagnosed with cancer at some point in their lifetimes," said Dr. Shu Li, LAM's Chairman. "With this in mind, it's important to know that more than 90 percent of people whose cancer is diagnosed at stage one have a 10-year survival rate, compared to just 5 percent for those whose cancer is found at stage four. The unique technology behind the IvyGene test – which is based on years of research, with tens of thousands of patients who have been studied in the clinic with AI / machine learning methods – represents a critical innovation in detecting cancer quickly, and its life-saving potential cannot be understated."

Unlike the majority of genetic tests that investigate DNA mutations to determine the propensity or possibility of developing cancer over time, the IvyGene test identifies DNA methylation patterns that are consistent with disease presence at the time of testing. So far, the IvyGene test and the underlying technology has been validated with four cancers—breast, colon, liver and lung—and is intended to be used in conjunction with other diagnostic and confirmatory tests, including mammograms, PET scans and biopsies.

"LAM's promising IvyGene test is truly a game-changer when it comes to detecting cancer accurately, especially since thousands of people in the U.S. alone are beginning their fights against the disease every day, and identifying its presence as early as possible is key to survival," added Dr. Mark Rosenberg, founder and medical director of the Advanced Medical Therapeutics, Institute for Healthy Aging, and Integrative Cancer Therapeutics. "The potential to confirm cancer using a simple blood test signals a hopeful future for improving the diagnosis, treatment options and prediction of prognosis in cancer as a whole."

For more information on the IvyGene test, visit https://www.ivygenelabs.com.

About Laboratory for Advanced Medicine
LAM is a clinical-stage medical technology company focused on developing cutting-edge non-invasive, nontoxic technologies for early diagnosis and intervention, possibly years before symptoms arise. LAM is dedicated to building and growing world-class technologies still in development from the laboratory to the clinic. LAM operates scientifically, ethically and efficiently to bring these cutting-edge technologies into the mainstream.

LAM is headquartered in the United States with offices in California, Texas and Indiana. LAM is a multi-national business with collaborations in both the U.S. and China, including leading scientists, physicians, research institutions and business leaders. LAM strives to combine the experiences of these innovators and achievers to provide the healthiest and safest diagnostic technologies to everyone.

LAM has CLIA registered and CAP accredited laboratories, third-party laboratories and cGMP facilities all working toward the endeavor of bringing these first-class technologies into the medical community.

About IvyGene®
The IvyGene technology is owned by the Laboratory for Advanced Medicine, Inc. The IvyGene test is a collection of blood tests based on the IvyGene technology platform, for detecting the presence of cancer and quantification of cancer presence. IvyGene utilizes a multi-target approach derived from advanced DNA sequencing methods to detect the DNA methylation pattern of cell-free DNA in blood. The sequence, along with the ratio of unmethylatedto methylated ctDNA, is consistent with cancer presence at the time of testing.

Unlike many genetic tests that use DNA to determine the propensity or possibility of developing cancer over time, the IvyGene test identifies DNA methylation patterns consistent with actual disease presence and quantification of cancer presence at the time of testing.

SOURCE Laboratory for Advanced Medicine